BRCA1 and pancreatic neoplasm: In addition, genetic testing guidelines are adapted too slowly to recent findings, e.g., germline genetic testing of BRCA1/2 in patients with pancreatic cancer to facilitate individualized therapies with the PARP inhibitor olaparib [41].